Generalized Myasthenia Gravis: Unlocking New Treatment Options to Advance Patient Care
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Activity Description
Generalized myasthenia gravis (gMG) is a rare, chronic disorder in which the immune system produces muscle receptor–specific antibodies that damage or inhibit neuromuscular junctions. The large majority of patients with gMG are classified into 1 or more of 3 subtypes, which are characterized by the specific antibodies produced. Patients of all gMG subtypes experience muscle weakness that may present across multiple muscle groups, significantly affecting quality of life. Further, the heterogeneous symptom profile complicates clinical assessment of disease severity and progression. Recently, a range of biologic agents have become available for immune system–directed management in patients with up to 2 gMG subtypes, including complement inhibitors (eculizumab, ravulizumab, and zilucoplan) and FcRn antagonists (efgartigimod and rozanolixizumab). Additional biologics under clinical investigation include B-cell inhibitors, T-cell inhibitors, and novel FcRn inhibitors (eg, nipocalimab and batoclimab), some of which have demonstrated efficacy in up to 3 gMG subtypes. In this CE activity, experts in the field explore the current tools for quantifying disease burden and severity in patients with gMG, review the pathophysiology of gMG and the significance of disease subtype on clinical decision-making, and report the latest clinical data on targeted therapies for management of patients with gMG.
Target Audience
The intended audience for this activity is neurologists involved in the management of patients with gMG.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Identify disease severity assessment tools to help guide timely interventions for patients with gMG.
- Outline how gMG pathophysiology guides treatment selection for patients.
- Assess the latest clinical data on targeted therapies to improve clinical decision-making for patients with gMG.
Activity Chair
Nicholas Silvestri, MD, FAAN
Professor of Neurology
University at Buffalo Jacobs School of Medicine & Biomedical Sciences
Buffalo, NY
Faculty
Carolina Barnett-Tapia, MD, PhD
Associate Professor, Department of Medicine
Division of Neurology
University of Toronto, Canada
Clinician Scientist, Division of Neurology
University Health Network
Toronto, Ontario, Canada
Neelam Goyal, MD
Clinical Professor
Stanford University
Palo Alto, CA
Kelly Graham Gwathmey, MD
Associate Professor of Neurology
Neuromuscular Division Chair
Department of Neurology
Virginia Commonwealth University
Richmond, VA
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 28, 2025, to February 27, 2026.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Carolina Barnett-Tapia, MD, PhD
Consultant: Alexion, Argenx, Janssen, Novartis, UCB
Speaker Contracted by Ineligible Company: Argenx
Independent Research Contractor: Alexion, Cartesian
Neelam Goyal, MD
Advisor: Alexion, Amgen, Argenx, EMD Serono, Janssen, UCB
Consultant: Argenx
Independent Research Contractor: Argenx
Kelly Graham Gwathmey, MD
Advisor: Alexion, Amgen, UCB
Speaker Contracted by Ineligible Company: Alexion, Argenx
Nicholas Silvestri, MD, FAAN
Consultant: Alexion, Amgen, Argenx, Immunovant, UCB
Speaker Contracted by Ineligible Company: Alexion, Argenx, UCB
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2025 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com